Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 46 entries
Sorted by: Best Match Show Resources per page
A four-drug combination therapy consisting of low-dose tacrolimus, low-dose mycophenolate mofetil, corticosteroids, and mizoribine in living donor renal transplantation: A randomized study.

SAGE open medicine

Yan TZ, Wu XQ, Rong L.
PMID: 27231549
SAGE Open Med. 2016 May 11;4:2050312116643672. doi: 10.1177/2050312116643672. eCollection 2016.

OBJECTIVE: We compared a three-drug combination therapy (control group) consisting of tacrolimus, mycophenolate mofetil, and corticosteroids in living donor renal transplantation with a four-drug combination therapy (study group), in which the doses of tacrolimus and mycophenolate mofetil were halved...

Cite
Yan TZ, Wu XQ, Rong L. A four-drug combination therapy consisting of low-dose tacrolimus, low-dose mycophenolate mofetil, corticosteroids, and mizoribine in living donor renal transplantation: A randomized study. SAGE Open Med. 2016;4:2050312116643672doi: 10.1177/2050312116643672.
Yan, T. Z., Wu, X. Q., & Rong, L. (2016). A four-drug combination therapy consisting of low-dose tacrolimus, low-dose mycophenolate mofetil, corticosteroids, and mizoribine in living donor renal transplantation: A randomized study. SAGE open medicine, 42050312116643672. https://doi.org/10.1177/2050312116643672
Yan, Tian-Zhong, et al. "A four-drug combination therapy consisting of low-dose tacrolimus, low-dose mycophenolate mofetil, corticosteroids, and mizoribine in living donor renal transplantation: A randomized study." SAGE open medicine vol. 4 (2016): 2050312116643672. doi: https://doi.org/10.1177/2050312116643672
Yan TZ, Wu XQ, Rong L. A four-drug combination therapy consisting of low-dose tacrolimus, low-dose mycophenolate mofetil, corticosteroids, and mizoribine in living donor renal transplantation: A randomized study. SAGE Open Med. 2016 May 11;4:2050312116643672. doi: 10.1177/2050312116643672. eCollection 2016. PMID: 27231549; PMCID: PMC4871204.
Copy Download .nbib Format: NLM
Maintenance treatment using the purine-synthesis inhibitor mizoribine in a patient with relapsing thrombotic thrombocytopenic purpura.

CEN case reports

Kawamura T, Usui J, Nagai K, Sakai K, Ebihara I, Yamagata K.
PMID: 29124560
CEN Case Rep. 2018 May;7(1):24-28. doi: 10.1007/s13730-017-0285-y. Epub 2017 Nov 09.

Thrombotic thrombocytopenic purpura (TTP) is a rare but life-threatening disease. Although plasma exchange (PE) therapy and corticosteroids are standard remission induction and maintenance therapies, some patients are easily refractory and frequently relapse under treatment with this therapy, and require...

Cite
Kawamura T, Usui J, Nagai K, et al. Maintenance treatment using the purine-synthesis inhibitor mizoribine in a patient with relapsing thrombotic thrombocytopenic purpura. CEN Case Rep. 2017;7(1):24-28doi: 10.1007/s13730-017-0285-y.
Kawamura, T., Usui, J., Nagai, K., Sakai, K., Ebihara, I., & Yamagata, K. (2018). Maintenance treatment using the purine-synthesis inhibitor mizoribine in a patient with relapsing thrombotic thrombocytopenic purpura. CEN case reports, 7(1), 24-28. https://doi.org/10.1007/s13730-017-0285-y
Kawamura, Tetsuya, et al. "Maintenance treatment using the purine-synthesis inhibitor mizoribine in a patient with relapsing thrombotic thrombocytopenic purpura." CEN case reports vol. 7,1 (2018): 24-28. doi: https://doi.org/10.1007/s13730-017-0285-y
Kawamura T, Usui J, Nagai K, Sakai K, Ebihara I, Yamagata K. Maintenance treatment using the purine-synthesis inhibitor mizoribine in a patient with relapsing thrombotic thrombocytopenic purpura. CEN Case Rep. 2018 May;7(1):24-28. doi: 10.1007/s13730-017-0285-y. Epub 2017 Nov 09. PMID: 29124560; PMCID: PMC5886917.
Copy Download .nbib Format: NLM
Steroid minimization immunosuppression protocol using basiliximab in adult living donor liver transplantation for hepatitis C virus-related cirrhosis.

Hepatology research : the official journal of the Japan Society of Hepatology

Hibi T, Shinoda M, Itano O, Obara H, Kitago M, Abe Y, Yagi H, Tanaka M, Hoshino K, Fujino A, Kuroda T, Kawachi S, Tanabe M, Shimazu M, Kitagawa Y.
PMID: 25594837
Hepatol Res. 2015 Dec;45(12):1178-84. doi: 10.1111/hepr.12486. Epub 2015 Feb 26.

AIM: Recent randomized trials have failed to prove the benefit of steroid-free immunosuppression in liver transplantation for hepatitis C virus (HCV)-related cirrhosis. Furthermore, there is a lack of data on the use of basiliximab in living donor liver transplantation...

Cite
Hibi T, Shinoda M, Itano O, et al. Steroid minimization immunosuppression protocol using basiliximab in adult living donor liver transplantation for hepatitis C virus-related cirrhosis. Hepatol Res. 2015;45(12):1178-84doi: 10.1111/hepr.12486.
Hibi, T., Shinoda, M., Itano, O., Obara, H., Kitago, M., Abe, Y., Yagi, H., Tanaka, M., Hoshino, K., Fujino, A., Kuroda, T., Kawachi, S., Tanabe, M., Shimazu, M., & Kitagawa, Y. (2015). Steroid minimization immunosuppression protocol using basiliximab in adult living donor liver transplantation for hepatitis C virus-related cirrhosis. Hepatology research : the official journal of the Japan Society of Hepatology, 45(12), 1178-84. https://doi.org/10.1111/hepr.12486
Hibi, Taizo, et al. "Steroid minimization immunosuppression protocol using basiliximab in adult living donor liver transplantation for hepatitis C virus-related cirrhosis." Hepatology research : the official journal of the Japan Society of Hepatology vol. 45,12 (2015): 1178-84. doi: https://doi.org/10.1111/hepr.12486
Hibi T, Shinoda M, Itano O, Obara H, Kitago M, Abe Y, Yagi H, Tanaka M, Hoshino K, Fujino A, Kuroda T, Kawachi S, Tanabe M, Shimazu M, Kitagawa Y. Steroid minimization immunosuppression protocol using basiliximab in adult living donor liver transplantation for hepatitis C virus-related cirrhosis. Hepatol Res. 2015 Dec;45(12):1178-84. doi: 10.1111/hepr.12486. Epub 2015 Feb 26. PMID: 25594837.
Copy Download .nbib Format: NLM
Long-term use of mizoribine in rheumatoid arthritis patients on hemodialysis.

Modern rheumatology

Saisho K, Kurosawa O, Fukanoki T, Hanafusa A, Tajima N.
PMID: 24383689
Mod Rheumatol. 2001 Jun;11(2):132-5. doi: 10.3109/s101650170024.

Abstract Small doses of mizoribine (MZR) were administered to five rheumatoid arthritis (RA) patients on hemodialysis (HD). A maintenance dose of 25 mg or less was administered either once per day or once following HD. The Lansbury activity index...

Cite
Saisho K, Kurosawa O, Fukanoki T, et al. Long-term use of mizoribine in rheumatoid arthritis patients on hemodialysis. Mod Rheumatol. 2001;11(2):132-5doi: 10.3109/s101650170024.
Saisho, K., Kurosawa, O., Fukanoki, T., Hanafusa, A., & Tajima, N. (2001). Long-term use of mizoribine in rheumatoid arthritis patients on hemodialysis. Modern rheumatology, 11(2), 132-5. https://doi.org/10.3109/s101650170024
Saisho, K, et al. "Long-term use of mizoribine in rheumatoid arthritis patients on hemodialysis." Modern rheumatology vol. 11,2 (2001): 132-5. doi: https://doi.org/10.3109/s101650170024
Saisho K, Kurosawa O, Fukanoki T, Hanafusa A, Tajima N. Long-term use of mizoribine in rheumatoid arthritis patients on hemodialysis. Mod Rheumatol. 2001 Jun;11(2):132-5. doi: 10.3109/s101650170024. PMID: 24383689.
Copy Download .nbib Format: NLM
Successful treatment of protein-losing gastroenteropathy with steroid pulse and immunosuppressive therapies in a patient with sjögren syndrome.

Case reports in gastroenterology

Nasu T, Miyata K, Uno A, Kawashima A, Kondo M, Akamizu T, Nakao T.
PMID: 21769290
Case Rep Gastroenterol. 2011;5(2):372-7. doi: 10.1159/000330197. Epub 2011 Jul 08.

We report the case of a 59-year-old female who developed facial edema together with hypoproteinemia. On the basis of (99m)Tc-human serum albumin scintigraphy and a1-antitrypsin clearance, she was diagnosed with protein-losing gastroenteropathy. Furthermore, she was diagnosed with Sjögren syndrome...

Cite
Nasu T, Miyata K, Uno A, et al. Successful treatment of protein-losing gastroenteropathy with steroid pulse and immunosuppressive therapies in a patient with sjögren syndrome. Case Rep Gastroenterol. 2011;5(2):372-7doi: 10.1159/000330197.
Nasu, T., Miyata, K., Uno, A., Kawashima, A., Kondo, M., Akamizu, T., & Nakao, T. (2011). Successful treatment of protein-losing gastroenteropathy with steroid pulse and immunosuppressive therapies in a patient with sjögren syndrome. Case reports in gastroenterology, 5(2), 372-7. https://doi.org/10.1159/000330197
Nasu, Tetsushi, et al. "Successful treatment of protein-losing gastroenteropathy with steroid pulse and immunosuppressive therapies in a patient with sjögren syndrome." Case reports in gastroenterology vol. 5,2 (2011): 372-7. doi: https://doi.org/10.1159/000330197
Nasu T, Miyata K, Uno A, Kawashima A, Kondo M, Akamizu T, Nakao T. Successful treatment of protein-losing gastroenteropathy with steroid pulse and immunosuppressive therapies in a patient with sjögren syndrome. Case Rep Gastroenterol. 2011;5(2):372-7. doi: 10.1159/000330197. Epub 2011 Jul 08. PMID: 21769290; PMCID: PMC3134061.
Copy Download .nbib Format: NLM
An 11-year-old girl with antineutrophil cytoplasmic antibody-associated glomerulonephritis identified by a school urinary screening program.

CEN case reports

Kanno S, Kawasaki Y, Maeda R, Miyazaki K, Ono A, Suzuki Y, Suyama K, Suzuki S, Hosoya M.
PMID: 28509205
CEN Case Rep. 2014 Nov;3(2):232-236. doi: 10.1007/s13730-014-0126-1. Epub 2014 May 27.

Antineutrophil cytoplasmic autoantibody-associated glomerulonephritis (GN) in childhood is rare and has a poor prognosis. We report an 11-year-old girl with renal-limited antineutrophil cytoplasmic autoantibody-associated vasculitis. Proteinuria and hematuria were first detected by a school urinary screening (SUS) program. Histopathological...

Cite
Kanno S, Kawasaki Y, Maeda R, et al. An 11-year-old girl with antineutrophil cytoplasmic antibody-associated glomerulonephritis identified by a school urinary screening program. CEN Case Rep. 2014;3(2):232-236doi: 10.1007/s13730-014-0126-1.
Kanno, S., Kawasaki, Y., Maeda, R., Miyazaki, K., Ono, A., Suzuki, Y., Suyama, K., Suzuki, S., & Hosoya, M. (2014). An 11-year-old girl with antineutrophil cytoplasmic antibody-associated glomerulonephritis identified by a school urinary screening program. CEN case reports, 3(2), 232-236. https://doi.org/10.1007/s13730-014-0126-1
Kanno, Shuto, et al. "An 11-year-old girl with antineutrophil cytoplasmic antibody-associated glomerulonephritis identified by a school urinary screening program." CEN case reports vol. 3,2 (2014): 232-236. doi: https://doi.org/10.1007/s13730-014-0126-1
Kanno S, Kawasaki Y, Maeda R, Miyazaki K, Ono A, Suzuki Y, Suyama K, Suzuki S, Hosoya M. An 11-year-old girl with antineutrophil cytoplasmic antibody-associated glomerulonephritis identified by a school urinary screening program. CEN Case Rep. 2014 Nov;3(2):232-236. doi: 10.1007/s13730-014-0126-1. Epub 2014 May 27. PMID: 28509205; PMCID: PMC5411572.
Copy Download .nbib Format: NLM
Favorable response to immunosuppressive combination therapy with mizoribine and azathioprine in children with primary sclerosing cholangitis.

Hepatology research : the official journal of the Japan Society of Hepatology

Tajiri H, Zen Y, Takano T, Brooks S.
PMID: 29059700
Hepatol Res. 2018 Mar;48(4):322-328. doi: 10.1111/hepr.12993. Epub 2017 Nov 16.

Primary sclerosing cholangitis (PSC), with no curative intervention, can progress to end-stage liver disease. Mizoribine, a purine antimetabolite, has never been used for the management of PSC. To evaluate the role of mizoribine with azathioprine we undertook a preliminary...

Cite
Tajiri H, Zen Y, Takano T, et al. Favorable response to immunosuppressive combination therapy with mizoribine and azathioprine in children with primary sclerosing cholangitis. Hepatol Res. 2017;48(4):322-328doi: 10.1111/hepr.12993.
Tajiri, H., Zen, Y., Takano, T., & Brooks, S. (2018). Favorable response to immunosuppressive combination therapy with mizoribine and azathioprine in children with primary sclerosing cholangitis. Hepatology research : the official journal of the Japan Society of Hepatology, 48(4), 322-328. https://doi.org/10.1111/hepr.12993
Tajiri, Hitoshi, et al. "Favorable response to immunosuppressive combination therapy with mizoribine and azathioprine in children with primary sclerosing cholangitis." Hepatology research : the official journal of the Japan Society of Hepatology vol. 48,4 (2018): 322-328. doi: https://doi.org/10.1111/hepr.12993
Tajiri H, Zen Y, Takano T, Brooks S. Favorable response to immunosuppressive combination therapy with mizoribine and azathioprine in children with primary sclerosing cholangitis. Hepatol Res. 2018 Mar;48(4):322-328. doi: 10.1111/hepr.12993. Epub 2017 Nov 16. PMID: 29059700.
Copy Download .nbib Format: NLM
Long-term prognosis of 4 children with steroid-sensitive nephrotic syndrome and relapse after 30 years of age.

CEN case reports

Motoyama O, Sakai K, Iitaka K.
PMID: 28509256
CEN Case Rep. 2014 May;3(1):106-109. doi: 10.1007/s13730-013-0096-8. Epub 2013 Sep 14.

Some children with steroid-sensitive nephrotic syndrome (SSNS) have been reported to suffer relapses in adulthood, but the clinical course of such adults is unclear. Four children with SSNS suffered relapses after 30 years of age. Those 4 patients developed...

Cite
Motoyama O, Sakai K, Iitaka K. Long-term prognosis of 4 children with steroid-sensitive nephrotic syndrome and relapse after 30 years of age. CEN Case Rep. 2013;3(1):106-109doi: 10.1007/s13730-013-0096-8.
Motoyama, O., Sakai, K., & Iitaka, K. (2014). Long-term prognosis of 4 children with steroid-sensitive nephrotic syndrome and relapse after 30 years of age. CEN case reports, 3(1), 106-109. https://doi.org/10.1007/s13730-013-0096-8
Motoyama, Osamu, et al. "Long-term prognosis of 4 children with steroid-sensitive nephrotic syndrome and relapse after 30 years of age." CEN case reports vol. 3,1 (2014): 106-109. doi: https://doi.org/10.1007/s13730-013-0096-8
Motoyama O, Sakai K, Iitaka K. Long-term prognosis of 4 children with steroid-sensitive nephrotic syndrome and relapse after 30 years of age. CEN Case Rep. 2014 May;3(1):106-109. doi: 10.1007/s13730-013-0096-8. Epub 2013 Sep 14. PMID: 28509256; PMCID: PMC5411542.
Copy Download .nbib Format: NLM
Involvement of Multiple Transporters-mediated Transports in Mizoribine and Methotrexate Pharmacokinetics.

Pharmaceuticals (Basel, Switzerland)

Murakami T, Mori N.
PMID: 24280676
Pharmaceuticals (Basel). 2012 Aug 10;5(8):802-36. doi: 10.3390/ph5080802.

Mizoribine is administered orally and excreted into urine without being metabolized. Many research groups have reported a linear relationship between the dose and peak serum concentration, between the dose and AUC, and between AUC and cumulative urinary excretion of...

Cite
Murakami T, Mori N. Involvement of Multiple Transporters-mediated Transports in Mizoribine and Methotrexate Pharmacokinetics. Pharmaceuticals (Basel). 2012;5(8):802-36doi: 10.3390/ph5080802.
Murakami, T., & Mori, N. (2012). Involvement of Multiple Transporters-mediated Transports in Mizoribine and Methotrexate Pharmacokinetics. Pharmaceuticals (Basel, Switzerland), 5(8), 802-36. https://doi.org/10.3390/ph5080802
Murakami, Teruo, and Mori, Nobuhiro. "Involvement of Multiple Transporters-mediated Transports in Mizoribine and Methotrexate Pharmacokinetics." Pharmaceuticals (Basel, Switzerland) vol. 5,8 (2012): 802-36. doi: https://doi.org/10.3390/ph5080802
Murakami T, Mori N. Involvement of Multiple Transporters-mediated Transports in Mizoribine and Methotrexate Pharmacokinetics. Pharmaceuticals (Basel). 2012 Aug 10;5(8):802-36. doi: 10.3390/ph5080802. PMID: 24280676; PMCID: PMC3763673.
Copy Download .nbib Format: NLM
Long-term post-marketing surveillance of mizoribine for the treatment of lupus nephritis: Safety and efficacy during a 3-year follow-up.

SAGE open medicine

Yagi N, Okada K, Sudo Y, Itoh H, Yoshida H, Kuroda T.
PMID: 26770729
SAGE Open Med. 2014 May 08;2:2050312114533960. doi: 10.1177/2050312114533960. eCollection 2014.

OBJECTIVE: To determine the safety and efficacy of long-term use of mizoribine by undertaking a 3-year post-marketing surveillance study.METHODS: Subjects were all lupus nephritis patients newly treated with mizoribine between 1 October 2003 and 30 September 2005 at contracted...

Cite
Yagi N, Okada K, Sudo Y, et al. Long-term post-marketing surveillance of mizoribine for the treatment of lupus nephritis: Safety and efficacy during a 3-year follow-up. SAGE Open Med. 2014;2:2050312114533960doi: 10.1177/2050312114533960.
Yagi, N., Okada, K., Sudo, Y., Itoh, H., Yoshida, H., & Kuroda, T. (2014). Long-term post-marketing surveillance of mizoribine for the treatment of lupus nephritis: Safety and efficacy during a 3-year follow-up. SAGE open medicine, 22050312114533960. https://doi.org/10.1177/2050312114533960
Yagi, Nobuyuki, et al. "Long-term post-marketing surveillance of mizoribine for the treatment of lupus nephritis: Safety and efficacy during a 3-year follow-up." SAGE open medicine vol. 2 (2014): 2050312114533960. doi: https://doi.org/10.1177/2050312114533960
Yagi N, Okada K, Sudo Y, Itoh H, Yoshida H, Kuroda T. Long-term post-marketing surveillance of mizoribine for the treatment of lupus nephritis: Safety and efficacy during a 3-year follow-up. SAGE Open Med. 2014 May 08;2:2050312114533960. doi: 10.1177/2050312114533960. eCollection 2014. PMID: 26770729; PMCID: PMC4607187.
Copy Download .nbib Format: NLM
Infliximab treatment for Crohn's disease in a patient with IgA nephropathy.

Clinical journal of gastroenterology

Ueno Y, Tanaka S, Onitake T, Hanaoka R, Yoshioka K, Ito M, Chayama K.
PMID: 26192790
Clin J Gastroenterol. 2009 Dec;2(6):380-383. doi: 10.1007/s12328-009-0112-x. Epub 2009 Oct 03.

We describe herein a case of IgA nephropathy in a 34-year-old woman with Crohn's disease (CD) treated with infliximab. CD first appeared at the age of 15 years. An elemental diet was started for remission maintenance. Ten years later,...

Cite
Ueno Y, Tanaka S, Onitake T, et al. Infliximab treatment for Crohn's disease in a patient with IgA nephropathy. Clin J Gastroenterol. 2009;2(6):380-383doi: 10.1007/s12328-009-0112-x.
Ueno, Y., Tanaka, S., Onitake, T., Hanaoka, R., Yoshioka, K., Ito, M., & Chayama, K. (2009). Infliximab treatment for Crohn's disease in a patient with IgA nephropathy. Clinical journal of gastroenterology, 2(6), 380-383. https://doi.org/10.1007/s12328-009-0112-x
Ueno, Yoshitaka, et al. "Infliximab treatment for Crohn's disease in a patient with IgA nephropathy." Clinical journal of gastroenterology vol. 2,6 (2009): 380-383. doi: https://doi.org/10.1007/s12328-009-0112-x
Ueno Y, Tanaka S, Onitake T, Hanaoka R, Yoshioka K, Ito M, Chayama K. Infliximab treatment for Crohn's disease in a patient with IgA nephropathy. Clin J Gastroenterol. 2009 Dec;2(6):380-383. doi: 10.1007/s12328-009-0112-x. Epub 2009 Oct 03. PMID: 26192790.
Copy Download .nbib Format: NLM
IgG4-Related Tubulointerstitial Nephritis Associated with Membranous Nephropathy in Two Patients: Remission after Administering a Combination of Steroid and Mizoribine.

Case reports in nephrology

Miyata KN, Kihira H, Haneda M, Nishio Y.
PMID: 25045552
Case Rep Nephrol. 2014;2014:678538. doi: 10.1155/2014/678538. Epub 2014 Jun 19.

We report two cases of Japanese men who presented with proteinuria, eosinophilia, hypocomplementemia, and high serum immunoglobulin G4 (IgG4) concentration and were diagnosed with membranous nephropathy associated with IgG4-related tubulointerstitial nephritis on renal biopsy. The typical renal lesions of...

Cite
Miyata KN, Kihira H, Haneda M, et al. IgG4-Related Tubulointerstitial Nephritis Associated with Membranous Nephropathy in Two Patients: Remission after Administering a Combination of Steroid and Mizoribine. Case Rep Nephrol. 2014;2014:678538doi: 10.1155/2014/678538.
Miyata, K. N., Kihira, H., Haneda, M., & Nishio, Y. (2014). IgG4-Related Tubulointerstitial Nephritis Associated with Membranous Nephropathy in Two Patients: Remission after Administering a Combination of Steroid and Mizoribine. Case reports in nephrology, 2014678538. https://doi.org/10.1155/2014/678538
Miyata, Kana N, et al. "IgG4-Related Tubulointerstitial Nephritis Associated with Membranous Nephropathy in Two Patients: Remission after Administering a Combination of Steroid and Mizoribine." Case reports in nephrology vol. 2014 (2014): 678538. doi: https://doi.org/10.1155/2014/678538
Miyata KN, Kihira H, Haneda M, Nishio Y. IgG4-Related Tubulointerstitial Nephritis Associated with Membranous Nephropathy in Two Patients: Remission after Administering a Combination of Steroid and Mizoribine. Case Rep Nephrol. 2014;2014:678538. doi: 10.1155/2014/678538. Epub 2014 Jun 19. PMID: 25045552; PMCID: PMC4089550.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 46 entries